Funding for this research was provided by:
National Cancer Institute (CA205607, CA167708)
Leukemia and Lymphoma Society of Canada (6472-15)
Teva Pharmaceutical Industries
Received: 5 April 2018
Accepted: 30 October 2018
First Online: 16 November 2018
Ethics approval and consent to participate
: This study was approved by the ethics committee of Virginia Commonwealth University (VCU). Patients signed a written informed consent form. Animal studies were conducted under protocol (AD20191) approved by VCU’s Institutional animal care and use committee (IACUC).
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.